Ensemble Therapeutics Corporation Achieves Milestone in Bristol-Myers Squibb Company Collaboration

Published: Apr 12, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced that it has achieved an important milestone in its research collaboration with Bristol-Myers Squibb Company (NYSE:BMY) by successfully developing Ensemblins against one of the designated key drug targets, resulting in an undisclosed milestone payment to Ensemble.

Back to news